Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW

被引：0

作者：

Andre, T. ^{[1
,2
]}

Lonardi, S. ^{[3
]}

Lenz, H. J. ^{[4
]}

Jensen, L. H. ^{[5
]}

Van Cutsem, E. ^{[6
,7
]}

Touchefeu, Y. ^{[8
]}

Garcia-Carbonero, R. ^{[9
]}

Tougeron, D. ^{[10
]}

Mendez, G. A. ^{[11
]}

Schenker, M. ^{[12
]}

de la Fouchardiere, C. ^{[13
]}

Limon, M. L. ^{[14
]}

Yoshino, T. ^{[15
]}

Li, J. ^{[16
]}

Manzano Mozo, J. L. ^{[17
]}

Cela, E. ^{[18
]}

Chen, T. ^{[19
]}

Lei, M. ^{[20
]}

Jin, L. ^{[21
]}

Elez Fernandez, M. E. ^{[22
]}

机构：

[1] Sorbonne Univ, Assistance Publ Hop Paris, Paris, France

[2] Hop St Antoine, Paris, France

[3] Veneto Inst Oncol IOV IRCCS, Med Oncol, Padua, Italy

[4] Univ Southern Calif, Med Oncol Dept, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA

[5] Univ Hosp Southern Denmark, Vejle Hosp, Dept Oncol, Vejle, Denmark

[6] Univ Hosp Gasthuisberg, Digest Oncol Dept, Leuven, Belgium

[7] Univ Leuven, KU Leuven, Leuven, Belgium

[8] Ctr Hosp Univ Nantes, Med Oncol, Nantes, France

[9] UCM, Hosp Univ Octubre Imas12 12, Med Oncol Dept, Madrid, Spain

[10] Ctr Hosp Univ Poitiers, Med Oncol, Poitiers, France

[11] Hosp Univ Fdn Favaloro, Oncol Dept, Buenos Aires, DF, Argentina

[12] Centrul Oncol Sf Nectarie, Med Oncol Dept, Craiova, Romania

[13] Ctr Leon Berard, Med Oncol Dept, Lyon, France

[14] Hosp Univ Virgen Rocio, Oncol Dept, Seville, Spain

[15] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Chiba, Japan

[16] Shanghai East Hosp, Med Oncol, Shanghai, Peoples R China

[17] Inst Catala Oncol, Med Oncol, Badalona, Spain

[18] Bristol Myers Squibb, Oncol Global Grp Dev, Princeton, NJ USA

[19] Bristol Myers Squibb, Stats, Princeton, NJ USA

[20] Bristol Myers Squibb, Translat Med, Princeton, NJ USA

[21] Bristol Myers Squibb, Oncol Clin Dev, Princeton, NJ USA

[22] Vall dHebron Univ Hosp & Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.610

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

541P

引用

页码：S451 / S452

页数：2

共 50 条

[21] Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus ipilimumab (IPI): CheckMate 142
Andre, T.
Overman, M.
Lonardi, S.
Aglietta, M.
McDermott, R.
Wong, K. Y. M.
Morse, M.
Hendlisz, A.
Moss, R. A.
Ledeine, J-M.
Tang, H.
Cao, Z. A.
Kopetz, S.
ANNALS OF ONCOLOGY, 2017, 28
[22] First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Lenz, Heinz-Josef
Van Cutsem, Eric
Limon, Maria Luisa
Wong, Ka Yeung Mark
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Luppi, Gabriele
Cardin, Dana B.
Dragovich, Tomislav
Shah, Usman
Abdullaev, Sandzhar
Gricar, Joseph
Ledeine, Jean-Marie
Overman, Michael James
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 161 - +
[23] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.
Chau, Ian
Ajani, Jaffer A.
Doki, Yuichiro
Xu, Jianming
Wyrwicz, Lucjan
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria Ignez Freitas Melro
Holtved, Eva
Murphy, Mariela A. Blum
Abdullaev, Sandzhar
Soleymani, Samira
Lei, Ming
Kato, Ken
Kitagawa, Yuko
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[24] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648
Chau, I.
Ajani, J.
Doki, Y.
Xu, J.
Wyrwicz, L.
Motoyama, S.
Ogata, T.
Kawakami, H.
Hsu, C.
Adenis, A.
El Hajbi, F.
Di Bartolomeo, M.
Braghiroli, M.
Holtved, E.
Murphy, M. Blum
Abdullaev, S.
Soleymani, S.
Lei, M.
Kato, K.
Kitagawa, Y.
ANNALS OF ONCOLOGY, 2022, 33 : S379 - S380
[25] Exploratory Analysis of Janus Kinase 1 (JAK1) Loss-of-Function (LoF) Mutations in Patients with DNA Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Metastatic Colorectal Cancer (mCRC) Treated with Nivolumab plus Ipilimumab in CheckMate-142
Kopetz, S.
Andre, T.
Overman, M. J.
Zagonel, V.
Lonardi, S.
Aglietta, M.
Gelsomino, F.
McDermott, R.
Wong, K. Y. M.
Hendlisz, A.
Alfonso, P. G.
Lenz, H. J.
Walsh, A.
Moss, R. A.
Greenawalt, D.
Cao, Z. A.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2018, 20 (03): : S3 - S3
[26] Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab plus ipilimumab in CheckMate-142
Kopetz, Scott
Andre, Theirry
Overman, Michael J.
Zagonel, Vittorina
Lonardi, Sara
Aglietta, Massimo
Gelsomino, Fabio
McDermott, Ray
Wong, Ka Yeung Mark
Hendlisz, Alain
Garcia Alfonso, Pilar
Lenz, Heinz-Josef
Walsh, Alice
Moss, Rebecca A.
Greenawalt, Danielle
Cao, Z. Alexander
CANCER RESEARCH, 2018, 78 (13)
[27] Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177.
Diaz, Luis A.
Le, Dung T.
Yoshino, Takayuki
Andre, Thierry
Bendell, Johanna C.
Koshiji, Minori
Zhang, Yinghua
Kang, S. Peter
Lam, Bao
Jaeger, Dirk
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup
Yoshino, T.
Andre, T.
Kim, T. W.
Yong, W. P.
Shiu, K-K.
Jensen, B. Vittrup
Jensen, L. H.
Punt, C. J. A.
Smith, D.
Garcia-Carbonero, R.
Alcaide-Garcia, J.
Gibbs, P.
de la Fouchardiere, C.
Rivera, F.
Elez Fernandez, M. E.
Le, D. T.
Zuo, Y.
Fogelman, D.
Adelberg, D. E.
Diaz, L.
ANNALS OF ONCOLOGY, 2023, 34 : S1502 - S1503
[29] Nivolumab in patients with DNA mismatch repairdeficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.
Overman, Michael J.
Bergamo, Francesca
McDermott, Raymond S.
Aglietta, Massimo
Chen, Franklin
Gelsomino, Fabio
Wong, Mark
Morse, Michael
Van Cutsem, Eric
Hendlisz, Alain
Neyns, Bart
Moss, Rebecca Anne
Zhao, Huanyu
Cao, Z. Alexander
Kamble, Shital
Kopetz, Scott
Andre, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[30] RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II study
Cohen, Romain
Bennouna, Jaafar
Henriques, Julie
Tournigand, Christophe
De La Fouchardiere, Christelle
Tougeron, David
Borg, Christophe
Mazard, Thibault
Chibaudel, Benoist
Garcia-Larnicol, Marie-Line
Svrcek, Magali
Vernerey, Dewi
Menu, Yves
Andre, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

← 1 2 3 4 5 →